कंपनी का अवलोकन
Strata Critical Medical, Inc. (SRTA) operates within the healthcare sector, specifically serving the medical care facilities industry by providing time-critical logistics and medical services across the United States. The company's operational model is divided into two distinct segments, Logistics and Clinical, offering essential air and ground transportation solutions for human organs and transplant teams. The firm currently employs 327 individuals and maintains a market capitalization of $359.27 million, reflecting its position as a mid-sized entity in the specialized medical logistics market. With annual revenue reaching $197.14 million, these financial figures indicate that the company has established a significant revenue base, suggesting a mature operational scale capable of managing substantial logistical volumes while maintaining a substantial workforce.
वित्तीय स्वास्थ्य
The company reported a revenue of $197.14 million for the trailing twelve months, yet recorded a net income of -$20,066,000 and an EBITDA of -$5,709,000, revealing a substantial gap where operating costs and expenses significantly exceed gross profits. The negative net income despite positive revenue highlights a cost structure characterized by high operating leverage or elevated expense ratios that currently suppress profitability. Free cash flow stands at -$26,982,624, which indicates that the company is consuming cash to fund its operations and growth initiatives rather than generating surplus liquidity for shareholder returns or aggressive debt reduction. Despite the negative cash flow, the balance sheet holds $61.23 million in cash against only $3.31 million in debt, creating a robust liquidity cushion. The debt-to-equity ratio of 1.19 suggests the company utilizes a moderate amount of leverage relative to its equity base, while the current ratio of 6.38 demonstrates an exceptionally strong short-term liquidity position with current assets significantly exceeding current liabilities. Furthermore, the return on equity is -8.0% and the return on assets is -2.7%, metrics that indicate management is currently generating negative returns on the capital invested, likely due to the heavy reinvestment required for expansion or maintaining service levels during a period of high revenue growth.
मूल्यांकन आकलन
The trailing P/E ratio and forward P/E ratio are both listed as N/A, implying that the lack of positive earnings prevents the calculation of standard price-to-earnings multiples, which typically signals a growth-stage or loss-making company where valuation relies on other drivers. The price-to-book ratio is 0.99, suggesting that the market values the company's equity at roughly equal to its book value, indicating no significant market premium or discount relative to the net asset value. Additionally, the price-to-sales ratio of 1.82 and the EV/EBITDA of -52.78 provide alternative valuation perspectives, showing that investors are pricing the stock based on revenue generation and enterprise value despite the negative earnings multiple. The 52-week high is $6.02 and the 52-week low is $2.48, meaning the stock price fluctuates within a range of nearly 60% at its extremes. The beta value is 2.11, which indicates that the stock's price volatility is more than twice as high as the broader market, exposing it to significant swings in investor sentiment and market conditions.
Growth & Income
The company demonstrated a revenue growth of 83.5% year-over-year, whereas the earnings growth is N/A due to the absence of positive net income, implying that top-line expansion is outpacing profitability in the current fiscal period. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all earnings and cash flows to fund internal growth, debt obligations, and operational scaling rather than distributing income to shareholders. This strategy of reinvesting earnings is typical for companies in high-growth phases that prioritize market share acquisition and infrastructure development over immediate income generation for investors. Overall, the growth and income profile is defined by aggressive revenue expansion and a complete absence of dividend income, focusing entirely on capital appreciation potential driven by the rapid increase in medical logistics demand.